In 2023, the number of confirmed Rifampicin Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Canada was recorded at 21. This number is forecasted to see a minimal increase over the next five years, reaching 23 cases by 2028. Between 2024 and 2028, the year-on-year variation remains relatively stable with increments less than 5%. The Compound Annual Growth Rate (CAGR) for this period is approximately 1.8%.
Looking ahead, important trends to watch for include the potential impact of public health interventions aimed at reducing RR-/MDR-TB and changes in healthcare policy. The emergence of new TB strains and advancements in treatment could also significantly influence future projections.
